BioSpace News Archive

BioIQ, an aggregator of testing solutions and optimizer of lab capacity for leading employers and health plans, today appointed Sean Slovenski as CEO. As the former head of Walmart Health, Slovenski led critical expansions of the company’s healthcare initiatives.

Change Healthcare (Nasdaq: CHNG) today announced it has acquired PROMETHEUS Analytics® from Altarum. PROMETHEUS Analytics is a leading reimbursement approach based on medical episodes of care, used by payer-provider collaborations nationwide, uniquely providing a fair and realistic blueprint for value-based payments.

Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC), a medical technology company driven to transform cancer surgery with advanced, real-time imaging tools to address areas of high unmet medical need, is pleased to announce that Mr. Aaron Davidson has been appointed to the Board of Directors, effective immediately.

TITAN Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today announced that it is scheduled to present at the LD 500 investor conference on Wednesday, September 2, 2020 at 11:20 AM ET.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company’s wholly owned subsidiary NuGenerex Health LLC has signed a joint venture agreement with Worldwide Digitech, LLC (WWDT) to form NuGenHealth LLC

SleepImage, a technology company offering FDA-cleared cloud-based Software as a Medical Device (SaMD) based on analyzing data collected with a single sensor to evaluate sleep quality and diagnose and manage sleep disorders in children and adults, will join the American Heart Association’s Center for Health Technology & Innovation’s

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to proceed with the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19,

Chemomab Ltd. announces that the European Commission has granted Orphan Drug Designation to its lead drug candidate CM-101 for the treatment of patients with Primary Sclerosing Cholangitis, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.

The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations.

Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, announced the completion of an oversubscribed $18.4 million private financing round.